Cargando…
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
Autores principales: | Schifanella, Luca, Barnett, Susan W., Bissa, Massimiliano, Galli, Veronica, Doster, Melvin N., Vaccari, Monica, Tomaras, Georgia D., Shen, Xiaoying, Phogat, Sanjay, Pal, Ranajit, Montefiori, David C., LaBranche, Celia C., Rao, Mangala, Trinh, Hung V., Washington-Parks, Robyn, Liyanage, Namal P. M., Gorini, Giacomo, Brown, Dallas R., Liang, Frank, Loré, Karin, Venzon, David J., Magnanelli, William, Metrinko, Michelle, Kramer, Josh, Breed, Matthew, Alter, Galit, Ruprecht, Ruth M., Franchini, Genoveffa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188203/ https://www.ncbi.nlm.nih.gov/pubmed/32343743 http://dx.doi.org/10.1371/journal.ppat.1008531 |
Ejemplares similares
-
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019) -
Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019) -
Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
por: Gorini, Giacomo, et al.
Publicado: (2020) -
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates
por: Silva de Castro, Isabela, et al.
Publicado: (2021) -
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)